Pfizer (PFE) Tops Q4 EPS by 7c; Guides FY 23 Below the Street

Pfizer (NYSE: PFE) reported Q4 EPS of $1.14, $0.07 better than the analyst estimate of $1.07. Revenue for the quarter came in at $24.29 billion versus the consensus estimate of $24.61 billion.

GUIDANCE:

Pfizer sees FY2023 EPS of $3.25-$3.45, versus the consensus of $4.44. Pfizer sees FY2023 revenue of $67-71 billion, versus the consensus of $74.13 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c